Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
CH3(OCH2CH2)nOH
CAS Number:
UNSPSC Code:
12162002
NACRES:
NA.23
MDL number:
Product Name
Poly(ethylene glycol) methyl ether, average Mn 20,000
vapor density
>1 (vs air)
Quality Level
vapor pressure
0.05 mmHg ( 20 °C)
form
powder or crystals
mol wt
average Mn 20,000
mp
64-69 °C
Mw/Mn
≤1.2
Ω-end
hydroxyl
α-end
methoxy
storage temp.
−20°C
SMILES string
O(CCO)C
InChI
1S/C3H8O2/c1-5-3-2-4/h4H,2-3H2,1H3
InChI key
XNWFRZJHXBZDAG-UHFFFAOYSA-N
Application
- Deoxycholic acid-grafted PEGylated chitosan micelles for the delivery of mitomycin C.: This study develops PEGylated chitosan micelles grafted with deoxycholic acid for effective delivery of mitomycin C, showcasing the potential of PEGylated compounds in pharmaceutical formulations and drug delivery systems (Zhang et al., 2015).
Still not finding the right product?
Explore all of our products under Poly(ethylene glycol) methyl ether
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
359.6 °F
flash_point_c
182 °C
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yiyi Yu et al.
Journal of pharmaceutical sciences, 102(3), 1054-1062 (2013-01-03)
To promote the application of methoxy poly(ethylene glycol)-cholesterol (mPEG-Chol), mPEG-Chol was used to prepare core-shell micelles encapsulating poorly water-soluble docetaxel (DTX-PM) by modified cosolvent evaporation method. Approaches to enhance DTX entrapment efficiency (EE) and minimize particle size were investigated in
Pengxiang Zhao et al.
Chemical communications (Cambridge, England), 49(31), 3218-3220 (2013-03-14)
"Click" chemistry now offers access to a great variety of triazoles, and the first example of a strategy to stabilize gold nanoparticles (AuNPs) with a new 1,2,3-triazole-mPEG ligand is developed here together with preliminary examples of possible applications.
Mulu Z Tesfay et al.
Journal of virology, 87(7), 3752-3759 (2013-01-18)
We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatment of multiple myeloma, an incurable malignancy of antibody-secreting plasma cells that are specifically localized in the bone marrow. One of the presumed advantages for using VSV as an oncolytic